Effectiveness and safety of reduced‐dose secukinumab switching to risankizumab for psoriasis patients in Asian population: A case series-Reference-Cited by-同舟云学术

Effectiveness and safety of reduced‐dose secukinumab switching to risankizumab for psoriasis patients in Asian population: A case series

Published:2023-04-09 Issue:7 Volume:32 Page:1048-1050
ISSN:0906-6705
Container-title:Experimental Dermatology
language:en
Short-container-title:Experimental Dermatology

Author:

Hsieh Chang‐Yu¹^ORCID,Tsai Tsen‐Fang¹^ORCID

Affiliation:

1. Department of Dermatology National Taiwan University Hospital Taipei City Taiwan

Publisher

Wiley

Subject

Dermatology,Molecular Biology,Biochemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/exd.14810

Reference7 articles.

1. Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement

2. Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study

3. Long-term effectiveness and safety of Ixekizumab in the treatment of 14 patients with a history of chronic erythrodermic psoriasis who failed prior secukinumab: A bicentric retrospective study

4. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the Susta IMM phase 2/3 trial

5. Efficacy and safety of risankizumab in psoriasis patients who had a suboptimal response to secukinumab or ixekizumab;Warren RB;Eur Acad Dermatol Venereol Congr,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis;Dermatology and Therapy;2024-07-29

2. Response to Biologic Therapy in Skin of Colour Participants With Moderate-to-Severe Psoriasis and Atopic Dermatitis: A Systematic Review;Journal of Cutaneous Medicine and Surgery;2024-06-07

3. Predictors for the effectiveness of 75 mg risankizumab in treating psoriasis—A real‐word evidence from a 52‐week retrospective study;Experimental Dermatology;2023-10-21